The European Medicines Agency has recommended the approval of the first histone deacetylase (HDAC) inhibitor for the treatment of multiple myeloma, a rare cancer of the white blood cells. The drug, Farydak (panobinostat), was developed by Novartis. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
